Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PONIF$0.12-0.00(-3.70%)Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering[6:15:00 PM ET]ELME$0.07-1.70(-96.19%)Elme Communities Announces Suspended NYSE Trading; Anticipates Trading Will Begin OTC Effective October 26, 2026[5:47:00 PM ET]HHH$73.09+3.60(+5.18%)Howard Hughes Holdings Set to Join S&P SmallCap 600 Howard Hughes Holdings Inc. (NYSE: HHH) will replace Arcosa Inc. (NYSE: ACA) in the S&P SmallCap 600 effective prior to the opening of trading on...[5:45:00 PM ET]ALGRF$0.400.00(0.00%)Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita[5:30:00 PM ET]ZEFIF$0.45+0.02(+3.56%)Zefiro Announces Closing of Non-Brokered Private Placement for Gross Proceeds of Approximately C$5.0 Million[5:29:00 PM ET]BLK$1,118.50-18.79(-1.65%)BlackRock® Canada Announces the Termination of iShares Convertible Bond Index ETF[5:23:34 PM ET]ITFS$1.43-0.02(-1.10%)Itafos Announces Release Date for Q3 2026 Results and Business Update Webcast[5:15:00 PM ET]FAGI$0.01-0.00(-13.33%)Full Alliance Group, Inc (OTC:FAGI) YAHBEE Highlights Community-Commerce Model for Agentic Commerce Era[5:15:00 PM ET]TGT$152.76-5.35(-3.38%)Vital Farms Introduces a Higher Standard for Free-Range Eggs Through Limited Pilot at Select Target Retail Stores[5:05:00 PM ET]NU$15.23+0.50(+3.39%)Notice to Market: Nu Holdings Ltd.[5:03:00 PM ET]POR$44.55-0.35(-0.78%)Portland General Electric Declares Dividend[5:00:00 PM ET]ANTX$3.55-0.09(-2.47%)AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)[5:00:00 PM ET]

REGN · NASDAQ

Regeneron Pharmaceuticals, Inc.

$804.00 -14.87 (-1.82%)

Company overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy, as well as macular edema following retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$82.8B
Employees
15,158
Headquarters
Tarrytown, NY
Website
regeneron.com
CEO
Leonard S. Schleifer
Listed
April 2, 1991
P/E
18.90
Dividend yield
0.46%

Company financials

Revenue
$14.9B
Gross profit
$12.6B
Operating income
$3.6B
EBITDA
$5.7B
Net income
$4.4B
EPS
$42.53
Total assets
$40.9B
Total debt
$2.7B
Gross margin
84.55%
Net margin
29.65%
Earnings yield
5.29%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

580.81653.12725.43797.74870.05
REGN 1D NASDAQ O809.01H825.52L800.00C819.09+13.42 (+1.67%)Vol852.59K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
REGN Stock news Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks Investment Research
REGN Stock news Regeneron: Is The Market Undervaluing Its Growth Potential Seeking Alpha
REGN Stock news Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market The Motley Fool
REGN Stock news Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Insider Sells $3,204,386.90 in Stock Defense World
REGN Stock news Regeneron’s Murphy sells $3.2 million in stock under plan (NASDAQ: REGN) Defense World
REGN Stock news Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share The Motley Fool
REGN Press release Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types GlobeNewswire
REGN Stock news Longleaf Partners Fund Q3 2026 Portfolio Review Seeking Alpha
REGN Stock news Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth Benzinga
REGN Stock news Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? Zacks Investment Research
REGN Press release Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension GlobeNewswire
REGN Press release Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 GlobeNewsWire
REGN Stock news Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data Benzinga
REGN Stock news Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript Seeking Alpha
REGN Press release Ubamatamab (MUC16xCD3) Shows a High Rate of Durable GlobeNewswire
REGN Press release Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean GlobeNewswire
REGN Press release Regeneron and Sanofi Expand Global Alliance with Multiple GlobeNewswire
REGN Press release Press Release: Sanofi and Regeneron expand global Alliance GlobeNewswire
REGN Stock news Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial Reuters
REGN Stock news Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Average Target Price of $802.18 Defense World
See more
FAQ

Questions about Regeneron Pharmaceuticals, Inc.

What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy, as well as macular edema following retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
What is REGN's market cap?
Regeneron Pharmaceuticals, Inc. (REGN) is a listed stock with a live quote. The latest market cap on this page is $82.8B.
Where is Regeneron Pharmaceuticals, Inc. headquartered?
Regeneron Pharmaceuticals, Inc. is headquartered in Tarrytown, NY.
How do I get REGN news from the API?
Call GET /v1/news?tickers=REGN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does REGN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for REGN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the REGN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs